CARLSBAD, California, April 23, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in spine and interventional spine technology that improves spinal surgery outcomes, today announced it will issue its financial results for the fourth quarter and fiscal year ended December 31, 2024, on Monday, April 28, 2025, after market hours. Management will host a conference call for investors on Tuesday, April 29, 2025 at 11:00 am ET/8:00am PT to discuss the results with investors.
Additionally, the Company wishes to clarify that the management information circulars issued in connection with its 2023 and 2024 annual meetings of shareholders inadvertently referenced a prior version of the Company’s stock option plan. The updated plan, which has been in effect since its approval by the board in 2022, included certain amendments that were not described in the circulars. The Company intends to include the correct version of the plan in the materials for its upcoming annual general meeting of shareholders, details of which will be announced in due course.
Fourth Quarter and Fiscal Year 2024 Conference Call Details
Date and Time: Tuesday, April 29, 2025, at 11:00 a.m. ET / 8:00 a.m. PT
Call-in Information: Interested parties can access the conference call by dialing (844) 861-5497 or (412) 317-5794.
Webcast: Interested parties can access the conference call via a live webcast, which is available via the following link: https://app.webinar.net/ZVY76PMx3gp.
Replay: A teleconference replay of the call will be available until May 6, 2025, at (877) 344-7529 or (412) 317-0088, replay access code 5737353. Additionally, a replay of the webcast will be available at https://app.webinar.net/ZVY76PMx3gp for 90 days.
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal implant market through a series of innovative, minimally invasive, regenerative spinal implant technologies. Additional information can be accessed at www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward-looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
Investor Contact
Adam Lowensteiner
Lytham Partners
(646) 829-9702
asapf@lythampartners.com
